



THERAMED HEALTH CORPORATION ANNOUNCES

COMPLETION OF PLAN OF ARRANGEMENT FOR EGF HEALTH HOLDINGS CORP.

VANCOUVER, BC, Friday July 19, 2019 – Theramed Health Corporation (CSE: TMED, OTCQB: EVAHF) (the “Company”) is pleased announce to that the plan of arrangement as previously announced March 17, 2017 and July 12, 2019, of its wholly owned subsidiary “EGF HEALTH HOLDINGS CORP.” (“EGF”) as a spin out is set to be effective today. EGF Health Holdings Corp.’s new CUSIP is 268470101 and its ISIN is CA2684701014.

New CEO and Director for EGF Health Holdings Corp.:

The Company is also pleased to announce the appointment of Chris Yu-Kai Hung as CEO and director in conjunction with the resignation of Syd Au as CEO; subject to any and all regulatory and corporate approvals. Mr. Hung is a capital markets and corporate finance professional with more than two decades of investment banking experience. He has served as CFO of an investment bank and has extensive experience in handling a wide variety of international merger and acquisition transactions.

Plan of Arrangement Details:

The Company has set the effective date as Friday, July 19, 2019 (the “Effective Date”) for its plan of arrangement dated February 6, 2017 (final court order March 16, 2017) with Theramed Health Corporation (“Theramed”) for its subsidiary EGF Health Holdings Corp. The Effective Date may be set separately for each subsidiary pursuant to the Arrangement as previously announced on March 17, 2017. Upon completion of the Arrangement and spin out of EGF from Theramed, EGF will become a public reporting issuer in provinces of Alberta and B.C.

THERAMED HEALTH CORPORATION

Email theramedhealthcorp@gmail.com

Website <http://www.theramedhealthcorp.com> <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcmartets.com/stock/EVAHF/news>

About THERAMED HEALTH

(CSE: TMED, OTCQB: EVAHF)

Theramed Health Corporation – is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company has recently been focused on utilizing CBD derived from Hemp as a core component. The company through its subsidiaries has assets and technologies involved in extracting and purifying CBD extracts, creating formulations through its key scientists, and with its medical device technology monitoring capabilities. Theramed’s unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated “CBD Health System” for monitoring, dosing, and recording the effects of CBD on your cardiovascular system.



Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.